Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 5
2019 2
2020 2
2021 12
2022 5
2023 7
2024 4
2025 7
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Göger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullén A; KEYNOTE-905/EV-303 Investigators. Vulsteke C, et al. N Engl J Med. 2026 Apr 2;394(13):1257-1269. doi: 10.1056/NEJMoa2511674. Epub 2026 Feb 18. N Engl J Med. 2026. PMID: 41707170 Clinical Trial.
BACKGROUND: Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. ...CONCLUSIONS: Perioperative enfortumab vedotin plus p …
BACKGROUND: Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy pro …
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Galsky MD, et al. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19. Future Oncol. 2021. PMID: 34008425 Free article.
Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite aggressive treatment. ...Recent Phase Ib/II studies suggest pembrolizumab monotherapy and combination therapy are effective neoadjuvant …
Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis desp …
Top advances of the year: Bladder cancer.
Apolo AB, Atiq S, Kydd AR, Chelluri R, Millan B, Gurram S, Chandran E, Simon N. Apolo AB, et al. Cancer. 2025 Aug 15;131(16):e70020. doi: 10.1002/cncr.70020. Cancer. 2025. PMID: 40782344 Review.
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug-delivery mechanisms in intravesical therapy for nonmuscle-invasive bladder cancer and muscle-invasive …
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) …
Immunotherapy in Bladder Cancer.
Konala VM, Adapa S, Aronow WS. Konala VM, et al. Am J Ther. 2022 May-Jun 01;29(3):e334-e337. doi: 10.1097/MJT.0000000000000934. Am J Ther. 2022. PMID: 30839322 Review.
BACKGROUND: Bladder cancer is the fifth most common cancer in the United States. Cisplatin-based chemotherapy is the current standard of care in stage IV bladder cancer. ...Atezolizumab and pembrolizumab are the Food and Drug Administration-approved ch …
BACKGROUND: Bladder cancer is the fifth most common cancer in the United States. Cisplatin-based chemotherapy is the current s …
Management of metastatic bladder cancer.
Nadal R, Bellmunt J. Nadal R, et al. Cancer Treat Rev. 2019 Jun;76:10-21. doi: 10.1016/j.ctrv.2019.04.002. Epub 2019 Apr 15. Cancer Treat Rev. 2019. PMID: 31030123 Review.
In the front-line setting, regulatory agencies have restricted the indications of atezolizumab and pembrolizumab (both ICIs) to patients with PD-L1positivity with advanced UC and who are platinum-ineligible. Very recently, erdafitinib, a pan-FGFR inhibitor, has been …
In the front-line setting, regulatory agencies have restricted the indications of atezolizumab and pembrolizumab (both ICIs) to patients wit …
Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP, Alberts AR, Iflé IG, Verhagen PCMS, van der Veldt AAM, Zuiverloon TCM. Scholtes MP, et al. Int J Mol Sci. 2021 Mar 11;22(6):2832. doi: 10.3390/ijms22062832. Int J Mol Sci. 2021. PMID: 33799514 Free PMC article. Review.
Immune checkpoint inhibition (ICI) or fibroblast growth factor receptor (FGFR) directed therapy are being evaluated for non-muscle invasive bladder cancer (NMIBC) patients, as well as muscle-invasive bladder cancer (MIBC …
Immune checkpoint inhibition (ICI) or fibroblast growth factor receptor (FGFR) directed therapy are being evaluated for non-muscle …
Novel Strategies and Therapeutic Advances for Bladder Cancer.
Ehrlich MI, Fox RD, Runcie KD, Stein MN, Wei AZ. Ehrlich MI, et al. Cancers (Basel). 2025 Jun 20;17(13):2070. doi: 10.3390/cancers17132070. Cancers (Basel). 2025. PMID: 40647372 Free PMC article. Review.
Background/Objectives: To summarize the relevant trials relating to novel strategies and therapeutic advances in the treatment of bladder cancer. Methods: A comprehensive review of the literature and recent/ongoing clinical trials was conducted, focusing on novel tr …
Background/Objectives: To summarize the relevant trials relating to novel strategies and therapeutic advances in the treatment of bladder …
Muscle invasive bladder cancer: where is the field headed?
Ghatalia P, Kaur J, Sonpavde G. Ghatalia P, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(9):913-927. doi: 10.1080/14712598.2023.2238607. Epub 2023 Jul 21. Expert Opin Biol Ther. 2023. PMID: 37477127 Review.
INTRODUCTION: The standard treatment for muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy or upfront radical cystectomy for cisplatin-ineligible patients. ...How …
INTRODUCTION: The standard treatment for muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadju …
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.
Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, Voog E, Eymard JC, Abraham C, Chasseray M, Lorgis V, Hilgers W, Gobert A, Le Moulec S, Simon C, Nicolas E, Escande A, Pouessel D, Mouillet G, Josse C, Solbes MN, Lambert P, Loriot Y. Barthélémy P, et al. Eur Urol Oncol. 2025 Apr;8(2):407-416. doi: 10.1016/j.euo.2024.09.014. Epub 2024 Oct 24. Eur Urol Oncol. 2025. PMID: 39448350 Free article.
In exploratory analyses of this population without disease progression on PBC, the median OS from the start of first-line PBC was 26.5 mo overall, and in subgroups that received second-line enfortumab vedotin (n = 55) or PBC (n = 79), it was 41.5 and 24.5 mo, respec …
In exploratory analyses of this population without disease progression on PBC, the median OS from the start of first-line PBC was 26.5 mo ov …
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R. Lopez-Beltran A, et al. Cancers (Basel). 2021 Jan 3;13(1):131. doi: 10.3390/cancers13010131. Cancers (Basel). 2021. PMID: 33401585 Free PMC article. Review.
A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the bladder. ...Nivolumab, a PD-1 antibody, also de …
A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patie …
50 results